Statement re. share price movement

8 August 2019

NMC Health plc

(the "Company" or "NMC")

Statement re. share price movement  

NMC Health plc (LSE: NMC), the leading private healthcare operator in the Gulf Cooperation Council (GCC) with international services across 19 countries, notes the recent share price weakness and confirms that it expects to report that, after a good performance in the first half of 2019, trading in the business remains in line with management expectations on all key metrics including revenue, EBITDA, net income, leverage, cash flow conversion and working capital. Full year guidance remains as previously stated.

In accordance with accounting requirements, the Company will be reporting its interim results on a post-IFRS 16 basis but intends to also provide pre-IFRS 16 comparators for the purposes of those sell-side research analysts that continue to forecast the Company's performance on such basis.

The Company will be able to comment in further detail and will be reporting its interim results on 22 August 2019 in line with the statement released on Monday 5 August 2019.

Contacts

About NMC Health

NMC is the leading private healthcare operator in the GCC with an international network of healthcare facilities across 19 countries. NMC ranks as one of the top two in-vitro fertilisation ("IVF") operators globally. The Group is recognised as a leading provider of long-term medical care in the UAE through its subsidiary ProVita. Pursing a selective international expansion program since 2016, the company now has total capacity of 3,109 beds across its network with 48% of this capacity in the Kingdom of Saudi Arabia (KSA), where the company has introduced long-term and multi-specialty care services. Moreover, the recent formation of a joint venture with GOSI/Hassana Investment Company provides a solid platform for continued growth in the GCC region's largest healthcare market. NMC treated over 7.5m patients in 2018. The Group is also a leading UAE supplier of products and consumables across several key market segments, with the major contribution coming from healthcare related products. The Group reported revenues of US$2.1 billion for the year ended 31 December 2018.

In April 2012 NMC was listed on the Premium Segment of the London Stock Exchange. NMC is a constituent of the FTSE 100 Index.